Login to Your Account

Financings Roundup

Cancer Drug Company ArQule Adds $54M In Public Offering

By Jennifer Boggs

Friday, June 15, 2007
While it awaits further Phase II data from its lead E21 Pathway activator in multiple cancer indications, ArQule Inc. padded its bank account with a $54.3 million public offering of 7 million shares priced at $7.75 each.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription